Vera Therapeutics (VERA) Total Debt (2021 - 2023)

Vera Therapeutics (VERA) has 3 years of Total Debt data on file, last reported at $3.1 million in Q1 2023.

• For the quarter ending Q1 2023, Total Debt fell 53.77% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2023 stood at $3.1 million (down 53.77% YoY), and the FY2022 full-year result was $2.8 million, down 53.84% from the prior year.
• Total Debt for Q1 2023 stood at $3.1 million, up from $2.8 million in the prior quarter.
• Across five years, Total Debt topped out at $6.7 million in Q2 2022 and bottomed at $994000.0 in Q3 2021.
• The 3-year median for Total Debt is $6.0 million (2022), against an average of $4.6 million.
• Peak annual rise in Total Debt reached 504.02% in 2022, while the deepest fall reached 53.84% in 2022.
• A 3-year view of Total Debt shows it stood at $6.0 million in 2021, then tumbled by 53.84% to $2.8 million in 2022, then gained by 10.43% to $3.1 million in 2023.
• The last three Total Debt figures came in at $3.1 million (Q1 2023), $2.8 million (Q4 2022), and $6.0 million (Q3 2022), per Business Quant data.

Peer Comparison